Literature DB >> 18328560

CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study.

Anu Usvasalo1, Suvi Savola, Riikka Räty, Kim Vettenranta, Arja Harila-Saari, Pirjo Koistinen, Eeva-Riitta Savolainen, Erkki Elonen, Ulla M Saarinen-Pihkala, Sakari Knuutila.   

Abstract

Deletion in chromosome 9p involving the CDKN2A locus (9p21.3) is known in many malignancies. To detect this deletion in adolescent ALL patients we used oligo array CGH and studied 54 patients aged 10-25 years. Deletion rate was 25/54 (46%), of these 19/25 (76%) were homozygous. Small deletions (<200 kb) were found in 8/25 (32%) and the smallest deletion was <30 kb. The only gene affected in all deletions was CDKN2A. We were unable to demonstrate prognostic value of the deletion, however patients with deletion belonged more often (P=0.06) to unfavorable biological category. Our results indicate that CDKN2A deletions <200 kb may not be detected by conventional methods.

Entities:  

Mesh:

Year:  2008        PMID: 18328560     DOI: 10.1016/j.leukres.2008.01.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  21 in total

1.  Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.

Authors:  Lina Shao; Sung-Hae L Kang; Jian Li; Patricia Hixson; Jesalyn Taylor; Svetlana A Yatsenko; Chad A Shaw; Aleksandar Milosavljevic; Chung-Che Chang; Sau Wai Cheung; Ankita Patel
Journal:  J Mol Diagn       Date:  2010-08-19       Impact factor: 5.568

Review 2.  Emerging technologies in paediatric leukaemia.

Authors:  Amanda Dixon-McIver
Journal:  Transl Pediatr       Date:  2015-04

Review 3.  Whole genome scanning as a cytogenetic tool in hematologic malignancies.

Authors:  Jaroslaw P Maciejewski; Ghulam J Mufti
Journal:  Blood       Date:  2008-05-27       Impact factor: 22.113

4.  A novel IGH@ gene rearrangement associated with CDKN2A/B deletion in young adult B-cell acute lymphoblastic leukemia.

Authors:  Moneeb A K Othman; Beata Grygalewicz; Barbara Pienkowska-Grela; Jolanta Rygier; Anna Ejduk; Martina Rincic; Joana B Melo; Isabel M Carreira; Britta Meyer; Thomas Liehr
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

5.  Pro-tumorigenic effects of miR-31 loss in mesothelioma.

Authors:  Sergey V Ivanov; Chandra M V Goparaju; Peter Lopez; Jiri Zavadil; Ginat Toren-Haritan; Shai Rosenwald; Moshe Hoshen; Ayelet Chajut; Dalia Cohen; Harvey I Pass
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

6.  Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia.

Authors:  Norma J Nowak; Sheila N J Sait; Amer Zeidan; George Deeb; Dan Gaile; Song Liu; LaurieAnn Ford; Paul K Wallace; Eunice S Wang; Meir Wetzler
Journal:  Cancer Genet Cytogenet       Date:  2010-05

Review 7.  Global genomic characterization of acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; James R Downing
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

8.  Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.

Authors:  Wanhua Zhang; Pu Kuang; Ting Liu
Journal:  Ann Med       Date:  2019-02-14       Impact factor: 4.709

9.  Ladder-like amplification of the type I interferon gene cluster in the human osteosarcoma cell line MG63.

Authors:  Narasimharao V Marella; Michael J Zeitz; Kishore S Malyavantham; Artem Pliss; Sei-ichi Matsui; Sandra Goetze; Juergen Bode; Ivan Raska; Ronald Berezney
Journal:  Chromosome Res       Date:  2008-11-15       Impact factor: 5.239

10.  Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood.

Authors:  Francesca Novara; Silvana Beri; Maria Ester Bernardo; Riccardo Bellazzi; Alberto Malovini; Roberto Ciccone; Angela Maria Cometa; Franco Locatelli; Roberto Giorda; Orsetta Zuffardi
Journal:  Hum Genet       Date:  2009-05-30       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.